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Background
Aromatic (lamotrigin, carbamazepine, phenobarbital) and
non aromatic antiepileptic (valproat, topiramate) drugs are
frequently associated with hypersensitivity reactions
mainly cutaneous such as maculopapular exanthems and
bullous and pustular eruptions on the basis of their clini-
cal, cellular and molecular pathophysiology. They usually
occur more than 1 hour after the last drug administration
and are self-limiting and benign. However, some severe
life-threatening reactions have been reported characterized
by high fever, malaise, erythema, skin blistering and
ulceration of mucous membrans, or hypersensitivity syn-
dromewith fever, lymphadenopaty and systemic symptoms
with cutaneous eruption. The underlying mechanisms of
these manifestations are not yet completely understood.
A cell-mediated pathogenic mechanism has been
demonstrated in some cases on the basis of positive patch
tests and/or lymphocyte transformation test. The arm of
this study was to confirm or rule out the diagnosis of
hypersensitivity reactions to antiepileptic drugs in children.
Method
At University Children’s Hospital in Belgrade a group of
62 children with suspected hypersensitivity reactions to
antiepileptic drugs were tested for the last 10 years. Out
of the total of 62 tested children, 28 were boys and 34
were girls. The ages ranged from 3 years to 17 years
(mean age 8.56). Various clinical reactions were described
as being induced by drugs (the number of patients affected
is shown in parentheses): maculopapular rash (37), macu-
lopapular rash and fever (2) urticaria (14), urticaria and
fever (5), urticaria and angioedema (4) The time period
that had elapsed from the occurrence of reaction to the
performance of patch tests varied from 1 month to one
year. Patch tests were performed with culprit drug such
as lamotrigine (in 30 children), valproat (in 5 child),
carbamazepine (in 24 children), and phenobarbital (in 3
children). In children with a history of mild hypersensitiv-
ity reactions and negative patch tests we performed
intradermal tests with culprit drugs.
Results
We found 42 positive patch tests: 18 with lamotrigine,
16 with carbamazepine, 5 with valproat and 3 with
phenobarbital. We also found 2 positive intradermal
tests only to lamotrigine. None of the 10 control group
children displayed positive responses to patch and intra-
dermal tests.
Conclusion
Our results demonstrate that patch tests are useful for
diagnosing anticonvulsant associated cutaneous hypersen-
sitivity reactions, and suggest an cell-mediated pathogenic
mechanism.
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